Researchers unravel mechanisms that produce individualized metabolism in leukemia
A research collaboration based in Kumamoto University (Japan) has shown that lysine-specific demethylase 1 (LSD1), an enzyme involved in gene expression, produces individualized metabolism depending on the type of acute myeloid leukemia cells. Cancer cells are known to have a unique ability to metabolize substances differently from normal cells, and this ability is considered to be a promising therapeutic target. The new research findings may contribute to the safe and effective use of LSD1 inhibitors as potential anticancer agents, and to the development of highly specific treatments for various leukemia types.
Acute myelogenous leukemia (AML) occurs when hematopoietic stem cells become tumors rather than differentiating into white or red blood cells. The various types of AML develop according to which stage of differentiation they become cancerous. Those that develop when differentiating into red bl
Increasing novel lncRNA in cardiomyocytes can inhibit the progression of heart failure
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Novel lncRNA, Caren, counteracts heart failure progression
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Anti-diabetic drug metformin inhibits disease progression in Alport syndrome mouse model
Researchers from Kumamoto University (Japan) have found that the anti-diabetic drug metformin significantly prolongs the survival of mice in a model that simulates the pathology of non-diabetic chronic kidney disease (ND-CKD) by ameliorating pathological conditions like reduced kidney function, glomerular damage, inflammation and fibrosis. Metformin s mechanism is different from existing therapeutics which only treat symptoms, such as the blood pressure drug losartan, so the researchers believe that a combination of these medications at low dose will be highly beneficial.
CKD (chronic kidney disease) is a general term for kidney damage that results from persistent decline in kidney function due to proteinuria, kidney inflammation, or fibrosis. As CKD progresses, patients are forced to undergo dialysis, and diabetes is one of its biggest risk factors. CKD can also occur in association with lifes
E-Mail
Credit: Professor Hirofumi Kai
Researchers from Kumamoto University (Japan) have found that the anti-diabetic drug metformin significantly prolongs the survival of mice in a model that simulates the pathology of non-diabetic chronic kidney disease (ND-CKD) by ameliorating pathological conditions like reduced kidney function, glomerular damage, inflammation and fibrosis. Metformin s mechanism is different from existing therapeutics which only treat symptoms, such as the blood pressure drug losartan, so the researchers believe that a combination of these medications at low dose will be highly beneficial.
CKD (chronic kidney disease) is a general term for kidney damage that results from persistent decline in kidney function due to proteinuria, kidney inflammation, or fibrosis. As CKD progresses, patients are forced to undergo dialysis, and diabetes is one of its biggest risk factors. CKD can also occur in association with lifestyle-related conditions such as hypertension, in